| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | $111,050,917 | 10,940,977 | RA Capital Management, L.P. | 29 Sep 2025 | |||
| Flynn James E | 7.8% | -12% | $134,624,739 | -$18,102,531 | 7,610,217 | -12% | Deerfield Management Company, L.P. | 30 Jul 2025 |
| BlackRock, Inc. | 5.1% | $58,401,450 | 5,013,000 | BlackRock, Inc. | 31 Dec 2025 |
As of 30 Sep 2025, 187 institutional investors reported holding 83,632,743 shares of ARS Pharmaceuticals, Inc. - Common Stock (SPRY). This represents 85% of the company’s total 98,294,118 outstanding shares.
The largest institutional shareholders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 10,860,977 | 0% | 1.3% | $109,152,819 |
| ORBIMED ADVISORS LLC | 8.4% | 8,288,510 | 0% | 2% | $83,299,526 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.6% | 7,503,812 | -23% | 1.2% | $75,413,311 |
| BlackRock, Inc. | 4.9% | 4,831,327 | +9.2% | 0% | $48,554,836 |
| Rubric Capital Management LP | 4.6% | 4,500,000 | +248% | 0.61% | $45,225,000 |
| SR One Capital Management, LP | 4.1% | 4,012,903 | 0% | 5.8% | $40,329,675 |
| VANGUARD GROUP INC | 3.6% | 3,500,303 | +7.3% | 0% | $35,178,046 |
| Aberdeen Group plc | 3.2% | 3,097,022 | +106% | 0.05% | $31,125,071 |
| STATE STREET CORP | 2.9% | 2,895,256 | +32% | 0% | $29,097,323 |
| ALLIANCEBERNSTEIN L.P. | 2.7% | 2,642,111 | -31% | 0.01% | $26,553,216 |
| FRANKLIN RESOURCES INC | 2.4% | 2,398,012 | +31% | 0.01% | $24,100,021 |
| Casdin Capital, LLC | 1.6% | 1,600,000 | 1.3% | $16,080,000 | |
| CITADEL ADVISORS LLC | 1.6% | 1,586,033 | -29% | 0.01% | $15,939,632 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 1,505,617 | +12% | 0% | $15,134,147 |
| Southpoint Capital Advisors LP | 1.5% | 1,500,000 | -12% | 0.4% | $15,075,000 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,325,739 | -9.5% | 0% | $13,323,677 |
| MPM BIOIMPACT LLC | 1.3% | 1,303,399 | 0% | 2.1% | $13,099,160 |
| BAMCO INC /NY/ | 1.3% | 1,268,532 | +3071% | 0.03% | $12,748,747 |
| Janney Montgomery Scott LLC | 1.2% | 1,213,020 | +105% | 0.03% | $12,191,000 |
| Qube Research & Technologies Ltd | 1.1% | 1,034,798 | 0.01% | $10,399,720 | |
| Eversept Partners, LP | 0.99% | 976,511 | 0.75% | $9,813,936 | |
| LEVIN CAPITAL STRATEGIES, L.P. | 0.78% | 764,294 | +164% | 0.7% | $7,681,155 |
| RAYMOND JAMES FINANCIAL INC | 0.77% | 756,347 | +12% | 0% | $7,601,289 |
| FMR LLC | 0.76% | 742,508 | -53% | 0% | $7,462,205 |
| MORGAN STANLEY | 0.71% | 700,414 | +83% | 0% | $7,039,160 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 3,750,736 | $43,696,124 | +$6,525,175 | $11.65 | 12 |
| 2025 Q3 | 83,632,743 | $840,434,931 | -$93,310,803 | $10.05 | 187 |
| 2025 Q2 | 84,521,210 | $1,475,027,148 | +$149,943,852 | $17.45 | 185 |
| 2025 Q1 | 76,226,291 | $958,937,759 | +$63,838,841 | $12.58 | 182 |
| 2024 Q4 | 71,304,827 | $752,320,202 | +$68,074,351 | $10.55 | 163 |
| 2024 Q3 | 63,765,651 | $925,913,322 | +$31,092,478 | $14.50 | 148 |
| 2024 Q2 | 62,590,275 | $533,041,807 | +$21,909,612 | $8.51 | 112 |
| 2024 Q1 | 59,892,345 | $612,088,771 | -$16,199,586 | $10.22 | 113 |
| 2023 Q4 | 65,423,068 | $358,517,051 | -$2,784,476 | $5.48 | 99 |
| 2023 Q3 | 66,524,840 | $251,464,826 | +$38,754,815 | $3.78 | 94 |
| 2023 Q2 | 55,071,412 | $368,976,724 | +$11,246,123 | $6.70 | 92 |
| 2023 Q1 | 53,405,274 | $347,669,060 | +$19,586,591 | $6.51 | 88 |
| 2022 Q4 | 50,164,476 | $427,856,540 | +$173,112,031 | $8.53 | 72 |
| 2022 Q3 | 30,422,972 | $160,377,408 | +$24,492,078 | $5.28 | 58 |
| 2022 Q2 | 26,061,019 | $110,514,000 | -$387,734 | $4.24 | 60 |
| 2022 Q1 | 26,983,988 | $94,707,000 | -$19,556,342 | $3.51 | 66 |
| 2021 Q4 | 30,103,833 | $200,460,000 | -$13,223,479 | $6.66 | 71 |
| 2021 Q3 | 28,894,700 | $288,363,500 | -$42,490,899 | $9.98 | 73 |
| 2021 Q2 | 27,989,545 | $864,603,729 | +$5,243,899 | $30.89 | 74 |
| 2021 Q1 | 27,691,694 | $1,205,836,321 | +$139,058,596 | $43.63 | 67 |
| 2020 Q4 | 24,444,347 | $1,127,544,026 | +$1,117,084,030 | $46.34 | 61 |